Gefitinib

概述规格名称和识别符技术文档高级数据系统学分类三维结构产品属性质检证书（CoA,COO,BSE/TSE 和分析图谱) 化学和物理性质安全和危险性（GHS）此产品的引用文献技术文档和文章引用文献溶液计算器常见问题

🧪

为什么选择此级别

，适用于对基线干扰要求严格的色谱和分析工作流程。

🌡

储存与运输

室温。常规运输。请查阅批次 COA 获取详细规格。

📋

质量文档

SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。

📚

文献证明

在色谱分析、有机合成和交叉偶联反应领域已被 40 篇同行评审文献引用。

概述

Gefitinib (ZD1839) (GMP) 是 GMP 级别的 Gefitinib。GMP 级别的小分子可用做细胞疗法中的辅助试剂。Gefitinib 是一种有效，选择性和口服活性的 EGFR 酪氨酸激酶抑制剂。

Gefitinib (ZD1839) (GMP) is Gefitinib produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor.

规格

英文名称

Gefitinib

储存条件

室温

运输条件

常规运输

名称和识别符

EC号

643-034-7

分子类型

小分子

IUPAC Name

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine

INCHI

1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)

InChi Key

XGALLCVXEZPNRQ-UHFFFAOYSA-N

Smiles

COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4

Isomeric SMILES

COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4

分子量

446.9

Reaxy-Rn

8949523

Reaxys-RN link address

https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=8949523&ln=

技术文档

📋 安全数据表 (SDS)

全面的危险、操作、储存及法规合规文件。

下载 SDS →

✅ 分析证书 (COA)

批次质量数据。输入批号以获取对应 COA。

查询 COA →

📊 产品数据表

产品规格和应用的快速参考摘要。

查看数据表 →

🔬 规格说明书

该级别的完整质量属性和验收标准。

查看规格说明 →

高级数据

系统学分类

分类树（Taxonomy Tree）

界（kingdom) 有机化合物
- 超类（Superclass) 有机杂环化合物
  - 类（Class) 二氮杂萘
    - 亚类（Subclass）苯二嗪类
      - 第5级 (level 5) 喹唑啉
        第6级 (level 6) 喹唑啉胺

界（kingdom)	有机化合物
超类（Superclass)	有机杂环化合物
类（Class)	二氮杂萘
亚类（Subclass）	苯二嗪类
中间层级节点（Intermediate Tree Nodes）	喹唑啉
直接上位类(Direct Parent)	喹唑啉胺
其他上位类（Alternative Parents）	苯胺和取代苯胺茴香醚烷基芳基醚氨基嘧啶及其衍生物氯苯类氟苯类芳基氯化物芳基氟化物吗啉咪唑内酰胺类杂芳族化合物三烷基胺二烷基醚氮杂环化合物氧环化合物仲胺碳氢化合物衍生物有机氯化物有机氟化物有机光子化合物
分子骨架（Molecular Framework)	芳香族杂多环化合物
取代基（Substituents）	芳基醚 - 氨基酸 - 氨基吡啶 - 苯胺或取代苯胺 - 茴香醚 - 芳香族杂多环化合物 - 芳基氯化物 - 芳基氟化物 - 芳基卤化物 - 氮杂环 - 苯基化合物 - 氯苯 - 二烷基醚 - 乙醚 - 氟萘 - 卤苯 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - 单环苯基基团 - Morpholine - 有机硝基化合物 - 有机氧化合物 - 有机氯化物 - 有机氟化物 - 有机卤化物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 氧杂环 - 氧杂吡嗪烷 - 嘧啶 - 萘啶吡啶 - 醛基 - 三元脂肪胺 - 三芳基胺
描述（Description）	该化合物属于喹唑啉胺类有机化合物。这类杂环芳香化合物含有喹唑啉骨架，其上取代有一个或多个胺基。
外部描述符（External Descriptors）	quinazolines - morpholines

三维结构

交互式化学结构模型

球棍
棍棒
线框模型
空间填充
显示氢气
动画

产品属性

ALogP	4.1

化学和物理性质

比旋光度

1.62

沸点

586.8 °C

熔点

194.0 to 198.0 °C

安全和危险性（GHS）

象形图

GHS05, GHS07, GHS08, GHS09

信号词

危险

危险声明

H302: 吞食有害

H315: 引起皮肤刺激

H318: 造成严重的眼睛损伤

H351: 怀疑引起遗传缺陷

H360: 可能损害生育力或未出生的孩子

H373: 通过长时间或反复暴露对器官造成损害

H401: 对水生生物有毒

H410: 对水生生物有剧毒并具有长期持续影响

预防措施声明

P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。

P264: 处理后要彻底洗手。

P270: 使用本产品时，请勿进食、饮水或吸烟。

P273: 避免释放到环境中。

P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。

P321: 特殊处理（请参阅此标签上的...）。

P330: 漱口

P391: 收集溢出物

P302+P352: 如皮肤沾染：用水充分清洗。

P362+P364: 脱掉沾污的衣服，清洗后方可重新使用。

P405: 密闭存放

P501: 将内容物/容器处理到。。。

P203: 使用前，获取、阅读并遵守所有安全说明。

P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。

P301+P317: 如果被吞咽：请寻求医疗帮助。

P305+P354+P338: 如果进入眼睛：立即用水冲洗几分钟。取下隐形眼镜（如果有的话），并且操作简单。继续冲洗。

P318: 如果暴露或担心，请就医。

P317: 寻求紧急医疗救助。

P332+P317: 如果出现皮肤刺激：请寻求医疗帮助。

P319: 如果你感到不适，请寻求医疗帮助。

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

技术文档和文章

GMP

目录：阿拉丁试剂的规格、级别和纯度

探索主题:

GMP

目录：阿拉丁试剂的规格、级别和纯度

探索主题:

GMP

PROTAC设计三要素：E3连接酶配体、Linker与靶蛋白配体（附阿拉丁试剂选型指南）

目录：技术文章

探索主题:

靶向蛋白降解 PROTAC 杂合双功能小分子化合物

Three Key Components of PROTAC Design: E3 Ligase Ligands, Linkers, and Target Protein Ligands (with an Aladdin Reagent Selection Guide)

目录：技术文章

探索主题:

PROTAC Protein degradation Hybrid bifunctional small molecule compound

甲氧基（–OCH₃）在已上市小分子药物中的结构功能解析：作用机制、证据链与产品选型导航（附相关产品表）

目录：技术文章

探索主题:

甲氧基

Structural–Functional Analysis of the Methoxy Group (–OCH₃) in Approved Small-Molecule Drugs: Mechanisms, Evidence Chains, and Product-Selection Navigation (with Related Product Tables)

目录：技术文章

探索主题:

–OCH₃

喹唑啉（Quinazoline，1,3-二氮杂萘）科研选型指南：结构特征、应用场景与关键试剂导航（表1–表4）

目录：技术文章

探索主题:

含氮芳香杂环喹唑啉

Quinazoline (Quinazoline, 1,3-Diazanaphthalene) Research Selection Guide: Structural Features, Application Scenarios, and Key Reagent Navigation (Tables 1–4)

目录：技术文章

探索主题:

Nitrogen-containing heterocycles Quinazoline

uPA/uPAR系统与细胞迁移及微环境重构

目录：技术文章

探索主题:

细胞外基质整合素蛋白水解纤溶酶 uPA uPAR 细胞迁移微环境重构

The uPA/uPAR System in Cell Migration and Microenvironment Remodeling

目录：技术文章

探索主题:

Extracellular matrix integrins proteolysis Plasmin uPA uPAR cell migration microenvironment remodeling

蛋白酪氨酸激酶/RTK信号转导机制与疾病研究

目录：技术文章

探索主题:

EGFR JAK FGFR VEGFR 蛋白酪氨酸激酶 RTK NRTK Src Abl 肿瘤靶向治疗

Protein Tyrosine Kinase/RTK Signal Transduction Mechanisms and Disease Research

目录：技术文章

探索主题:

EGFR JAK FGFR VEGFR RTK NRTK Src Abl protein tyrosine kinase tumor targeted therapy

MAPK/ERK 信号通路：RAS–RAF–MEK–ERK 级联调控、细胞功能输出与研究工具应用

目录：技术文章

探索主题:

FGF EGF PDGF ERK1 MAPK3 ERK2 MAPK1

MAPK/ERK Signaling Pathway: RAS–RAF–MEK–ERK Cascade Regulation, Cellular Functional Outputs, and Research Tool Applications

目录：技术文章

探索主题:

FGF EGF PDGF ERK1 MAPK3 ERK2 MAPK1

HER3信号网络在肿瘤进展、治疗耐药与靶向干预中的作用

目录：技术文章

探索主题:

抗体偶联药物 EGFR PI3K/AKT HER2 HER3 ERBB3 NRG1 异源二聚化治疗耐药双特异性抗体

Role of the HER3 Signaling Network in Tumor Progression, Therapeutic Resistance, and Targeted Intervention

目录：技术文章

探索主题:

EGFR PI3K/AKT HER2 HER3 ERBB3 NRG1 heterodimerization therapeutic resistance bispecific antibody antibody-drug conjugate

非小细胞肺癌的分子分型、驱动靶点与耐药机制

目录：技术文章

探索主题:

靶向治疗 KRAS 免疫检查点 EGFR ALK HER2 耐药机制非小细胞肺癌分子分型 ROS1 BRAF RET MET PIK3CA

Molecular Classification, Oncogenic Drivers, and Resistance Mechanisms of Non-Small Cell Lung Cancer

目录：技术文章

探索主题:

Targeted therapy KRAS Immune checkpoint EGFR ALK HER2 Resistance Mechanism ROS1 BRAF RET MET PIK3CA non-small cell lung cancer molecular classification

此产品的引用文献

如何在您的发表作品中引用阿拉丁的产品和网站? 引用文献检索

引用文献

1. Jiali Wang, Xianhai He, Zhirong Jia, Aiwen Yan, Kang Xiao, Shuo Liu, Mengjun Hou, Yaling Long, Xuansheng Ding. (2023) Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway. PHARMACEUTICAL BIOLOGY, [PMID:38100532] [10.1080/13880209.2023.2292266]
2. Yong Huang, Yi Lin, Bowen Li, Fu Zhang, Chenyue Zhan, Xin Xie, Zhuo Yao, Chongzhi Wu, Yuan Ping, Jianliang Shen. (2023) Combination therapy to overcome ferroptosis resistance by biomimetic self-assembly nano-prodrug. Asian Journal of Pharmaceutical Sciences, [PMID:37915761] [10.1016/j.ajps.2023.100844]
3. Yao Liu, Zhichao He, Heng Liang, Minzhen Han, Jinxingyi Wang, Qian Liu, Yanping Guan. (2023) A high-throughput UHPLC-MS/MS method for the determination of eight anti-tumor drugs in plasma. ANALYTICAL BIOCHEMISTRY, [PMID:37429484] [10.1016/j.ab.2023.115230]
4. Fangjun Chen, Wenda Chen, Zhenxin Wang, Yingfei Peng, Beili Wang, Baishen Pan, Wei Guo. (2023) Development and clinical application of a liquid chromatography-tandem mass spectrometry-based assay to quantify eight tyrosine kinase inhibitors in human plasma. Journal of Mass Spectrometry and Advances in the Clinical Lab, [PMID:37234251] [10.1016/j.jmsacl.2023.05.001]
5. Zhenzhen Pan, Qiufang Chen, Xiulan Zheng, Kai Wang, Yalei Duan, Kang Xiao, Zhirong Jia, Xuansheng Ding. (2023) JuBei Oral Liquid Induces Mitochondria-Mediated Apoptosis in NSCLC Cells. OncoTargets and Therapy, [PMID:32821122] [10.2147/OTT.S254464]
6. Jiabin Zhou, Yuhan Liu, Jun Chen, Nanxiang Xiong, Dongye Yi. (2023) Kaempferol suppresses glioma progression and synergistically enhances the antitumor activity of gefitinib by inhibiting the EGFR/SRC/STAT3 signaling pathway. DRUG DEVELOPMENT RESEARCH, 84 (3): (582-600). [PMID:36852868] [10.1002/ddr.22048]
7. Yin Xiaoting, Ma Suzhen, Li Mengyuan, Lu Shuaifei, Zhang Changjing, Liu Hui, Li Caiyin, Su Pan, Bai Ming, Li Yucheng. (2023) Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells. JOURNAL OF PHARMACY AND PHARMACOLOGY, 75 (3): (407-414). [PMID:36656101] [10.1093/jpp/rgac091]
8. Hao Chi, Sheng Tian, Xiu Li, Yuchu Chen, Qiumin Xu, Qixiao Wang, Wenwan Shi, Michael Adu-Frimpong, Shanshan Tong. (2023) Construction of lipid raft-coupled agarose gels as bioaffinity chromatography materials and validation with tropomyosin-related kinase A-targeted drugs. JOURNAL OF CHROMATOGRAPHY A, [PMID:36731332] [10.1016/j.chroma.2023.463803]
9. Jianbo Lin, Rujie Zheng, Liping Huang, Yuanrong Tu, Xu Li, Jianfeng Chen. (2022) Folic acid-mediated MSNs@Ag@Geb multifunctional nanocomposite heterogeneous platform for combined therapy of non-small cell lung cancer. COLLOIDS AND SURFACES B-BIOINTERFACES, [PMID:35759894] [10.1016/j.colsurfb.2022.112639]
10. Yulin Jiang, Jing Wang, Juehan Wang, Yi Zhuang, Lin Qi, Ganjun Feng, Li Zhang. (2022) Fabrication of novel PNIPAM@GO microspheres loaded with dual drugs featuring on-demand drug release capability. JOURNAL OF APPLIED POLYMER SCIENCE, 139 (27): (e52444). [10.1002/app.52444]
11. Pan Zhenzhen, Wang Kai, Wang Xiniao, Jia Zhirong, Yang Yuqi, Duan Yalei, Huang Lianzhan, Wu Zhuo-Xun, Zhang Jian-ye, Ding Xuansheng. (2022) Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression. Molecular Cancer, 21 (1): (1-17). [PMID:35303882] [10.1186/s12943-022-01547-3]
12. Yan Zhang, Pei Ma, Zhiguang Duan, Yannan Liu, Yu Mi, Daidi Fan. (2022) Ginsenoside Rh4 Suppressed Metastasis of Lung Adenocarcinoma via Inhibiting JAK2/STAT3 Signaling. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23 (4): (2018). [PMID:35216134] [10.3390/ijms23042018]
13. Yuqin Zhou, Weitong Hu, Xiangli Zhang, Yi Wang, Wenya Zhuang, Fengzhi Li, Qingyong Li. (2021) Cellular Uptake and Transport Characteristics of FL118 Derivatives in Caco-2 Cell Monolayers. CHEMICAL & PHARMACEUTICAL BULLETIN, 69 (11): (1054-1060). [PMID:34719586] [10.1248/cpb.c21-00467]
14. Fangyin Zhu, Liang Xu, Xudong Li, Ziying Li, Jun Wang, Haijun Chen, Xiumei Li, Yu Gao. (2021) Co-delivery of gefitinib and hematoporphyrin by aptamer-modified fluorinated dendrimer for hypoxia alleviation and enhanced synergistic chemo-photodynamic therapy of NSCLC. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, [PMID:34520834] [10.1016/j.ejps.2021.106004]
15. Zhao-Yang Wang, Hai-Long Wu, Yue-Yue Chang, Tong Wang, Wei Chen, Gao-Yan Tong, Ru-Qin Yu. (2021) Simultaneous determination of nine tyrosine kinase inhibitors in three complex biological matrices by using high-performance liquid chromatography–diode array detection combined with a second-order calibration method. JOURNAL OF SEPARATION SCIENCE, 44 (21): (3914-3923). [PMID:34463059] [10.1002/jssc.202100293]
16. Tianming Dai, Weifan Jiang, Min Wang, Zizheng Guo, Renke Dai. (2021) Influence of two-period cross-over design on the bioequivalence study of gefitinib tablets in beagle dogs. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, [PMID:34260895] [10.1016/j.ejps.2021.105933]
17. Jiang Yuhong, Zhuo Xin, Fu Xiujuan, Wu Yue, Mao Canquan. (2021) Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation. Frontiers in Pharmacology, [PMID:33967759] [10.3389/fphar.2021.625289]
18. Yue-Yue Chang, Hai-Long Wu, Huan Fang, Tong Wang, Yang-Zi Ouyang, Xiao-Dong Sun, Gao-Yan Tong, Yu-Jie Ding, Ru-Qin Yu. (2020) Comparison of three chemometric methods for processing HPLC-DAD data with time shifts: Simultaneous determination of ten molecular targeted anti-tumor drugs in different biological samples. TALANTA, [PMID:33379025] [10.1016/j.talanta.2020.121798]
19. Zhixiong Hu, Xin-Yue Jiao, Li Xu. (2019) The N,S co-doped carbon dots with excellent luminescent properties from green tea leaf residue and its sensing of gefitinib. MICROCHEMICAL JOURNAL, [10.1016/j.microc.2019.104588]
20. Tianhua Liu, Ling Zuo, Dongqing Guo, Xinlou Chai, Jie Xu, Zhaorui Cui, Zhiyi Wang, Chunying Hou. (2019) Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway. BIOMEDICINE & PHARMACOTHERAPY, [PMID:31629252] [10.1016/j.biopha.2019.109483]
21. Zhou Leilei, Weng Qi, Zheng Yixin, Zhou Yuqin, Li Qingyong, Li Fengzhi. (2019) Uptake and efflux of FL118 and two FL118 derivatives in 3D cell model. CYTOTECHNOLOGY, 71 (4): (785-795). [PMID:31309350] [10.1007/s10616-019-00322-5]
22. Weng Qi, Zhou Leilei, Xia Lihua, Zheng Yixin, Zhang Xiangli, Li Fengzhi, Li Qingyong. (2019) In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 84 (3): (527-537). [PMID:31030236] [10.1007/s00280-019-03846-x]
23. Yang Lehe, Lin Shichong, Kang Yanting, Xiang Youqun, Xu Lingyuan, Li Jifa, Dai Xuanxuan, Liang Guang, Huang Xiaoying, Zhao Chengguang. (2019) Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 38 (1): (1-13). [PMID:30674340] [10.1186/s13046-018-1015-9]
24. Xuanxuan Dai, Junru Zhang, Guilong Guo, Yuepiao Cai, Ri Cui, Changtian Yin, Weidong Liu, Rajamanickam Vinothkumar, Tingting Zhang, Guang Liang, Xiaohua Zhang. (2018) A mono-carbonyl analog of curcumin induces apoptosis in drug-resistant EGFR-mutant lung cancer through the generation of oxidative stress and mitochondrial dysfunction. Cancer Management and Research, [PMID:30214301] [10.2147/CMAR.S159660]
25. Guan Huang, Yanli Tong, Qidi He, Jie Wang, Zuanguang Chen. (2017) Aucklandia lappa DC. extract enhances gefitinib efficacy in gefitinib-resistance secondary epidermal growth factor receptor mutations. JOURNAL OF ETHNOPHARMACOLOGY, [PMID:28619365] [10.1016/j.jep.2017.06.011]
26. Yun-Yun Xi, Qing Tang, Ying Huang, Zhu Tao, Sai-Feng Xue, Qingdi Zhou, Gang Wei. (2017) A novel fluorescent indicator displacement assay for sensing the anticancer drug gefitinib. SUPRAMOLECULAR CHEMISTRY, [10.1080/10610278.2016.1202413]
27. Peng Mei, Huang Yanjun, Tao Ting, Peng Cai-Yun, Su Qiongli, Xu Wanjun, Darko Kwame Oteng, Tao Xiaojun, Yang Xiaoping. (2016) Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk. Scientific Reports, 6 (1): (1-10). [PMID:27334428] [10.1038/srep28611]
28. Li Chenjia, Liao Qi, Wang Rui, Zhang Xinping, Ma Mengyang, Liu Yonghong, Xiao Lei, Jiao Ying, Wang Nan. (2024) An OPRM1-SNAP-tag/CMC method to directly identify drug components in sewage. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, [PMID:39613988] [10.1007/s00216-024-05672-4]
29. Zhihong Hu, Xixi Hou, Yongjing Ren, Ziyuan Wu, Dong Yan, Hong Chen, Lan Wang. (2025) Anti-cancer activity of synthetic gefitinib-1,2,3-triazole derivatives against Hela cells via induction of apoptosis. Frontiers in Chemistry, [PMID:39926646] [10.3389/fchem.2025.1456743]
30. Wu Yu, Shi Xiao-Jie, Dai Xin-Yi, Song Tian Shun, Li Xiang-Ling, Xie Jing Jing. (2024) Biogated mesoporous silica nanoagents for inhibition of cell migration and combined cancer therapy. MICROCHIMICA ACTA, 191 (6): (1-9). [PMID:38740583] [10.1007/s00604-024-06401-5]
31. Yuan Liang, Qing Wang, Dianwen Zhang, Yiyao Gong, Qiuyan Jiang, Cong Ma, Libo Si, Tiehua Zhang, Jie Zhang, Zheng Ma. (2024) Ginsenoside CK ameliorates tumor growth in lung cancer mice via inhibiting EGFR. Journal of Functional Foods, [10.1016/j.jff.2024.106446]
32. Min Li, Shuaijun Peng, Jingjing Bu, Siqi Quan, Liming Liu, Zhouli Yue, Linlin Wang, Yucheng Li. (2025) Glycyrrhizic acid alleviates gefitinib-induced liver injury by regulating the p53/p21 pathway and releasing cell cycle arrest. FOOD AND CHEMICAL TOXICOLOGY, [PMID:40122507] [10.1016/j.fct.2025.115405]
33. Yilan Huang, Siwei Wang, Xiaojun Zhang, Chen Yang, Sikai Wang, Hongxia Cheng, Aiwu Ke, Chao Gao, Kun Guo. (2024) Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway. PHARMACOLOGICAL RESEARCH, [PMID:38280440] [10.1016/j.phrs.2024.107082]
34. Xinyi Lv, Yuehan Song, Tianhua Liu, Dingdan Zhang, Xinpeng Ye, Qingqing Wang, Rongrong Li, Jiayi Chen, Shujing Zhang, Xue Yu, Chunying Hou. (2025) Ginsenoside Rg3 Adjunctively Increases the Efficacy of Gefitinib Against NSCLC by Regulating EGFR Copy Number. Pharmaceuticals, 18 (7): (1077). [PMID:40732366] [10.3390/ph18071077]
35. Gen Li, Chunxiu Cai, Ning Zhang, Zijia Wang, Mingzhe Zhang, Quan Liu, Siyu Chen, Yanfei Shang, Chengqing Zhao, Shenzhen Ren, Hailong An. (2025) Carrier-free procyanidin-ferric nanonetworks loading gefitinib to inhibit TMEM16A-EGFR mutual activation loop for photothermally enhanced breast cancer targeted therapy. Materials Today Bio, [PMID:41158712] [10.1016/j.mtbio.2025.102426]
36. Cong Xie, Tongshu Guan, Jin Huang, Jiayu Chen, Yilei Li, Ping Zheng. (2025) Cyp3a4-Mediated in vitro Metabolism and in vivo Disposition of Lorlatinib in Rats. Drug Design Development and Therapy, [PMID:41169706] [10.2147/DDDT.S565228]
37. Xinying Ni, Hong Wang, Wenwen Chen, Xiao Meng, Mengping Zhang, Hua Shao, Fang Zhang, Cuijuan Wang. (2026) Field-ready detection of antineoplastic drugs in workplaces using a wearable flexible surface-enhanced Raman spectroscopy platform. SENSORS AND ACTUATORS B-CHEMICAL, [10.1016/j.snb.2026.139447]
38. Deng Yiting, Li Jin, Wang Peng, Luo Xuelian, Xu Hongxia, Xiao Yu, Wang Zhenchuan, Lu Yifei, Chen Ying, Ge Feng. (2026) DNAJB6 as an immuno-oncogenic hub in liver hepatocellular carcinoma: multi-omic profiling reveals prognostic significance and therapeutic vulnerability. JOURNAL OF MOLECULAR HISTOLOGY, 57 (1): (57). [PMID:41559348] [10.1007/s10735-026-10717-2]
39. Jiansong Zhao, Tian Yin, Yaxin Deng, Hongbing Liu, Mingli Wei, Chenxiao Chu, Xinxin Liang, Xiaoshuang Bi, Haibing He, Jingxin Gou, Xing Tang, Yu Zhang. (2026) Harnessing semen-derived exosomes for noninvasive fundus drug delivery: A paradigm for exosome-based ocular fundus therapeutics. Science Advances, 12 (13): [PMID:41894499] [10.1126/sciadv.adw7275]
40. Xu-Mei Gan, Wei-Jie Chen, Yu-Hang Xie, Cui-Xia Wang, Yan-Qiu Deng, Zhen-Wei Zhang. (2026) Dihydropyrano[2,3-b]indoles: Novel dual modulators for lung cancer treatment via autophagy inhibition and ferroptosis induction. BIOORGANIC CHEMISTRY, [PMID:42413401] [10.1016/j.bioorg.2026.110188]